0001127602-17-003935.txt : 20170203
0001127602-17-003935.hdr.sgml : 20170203
20170203172503
ACCESSION NUMBER: 0001127602-17-003935
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170201
FILED AS OF DATE: 20170203
DATE AS OF CHANGE: 20170203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GILEAD SCIENCES INC
CENTRAL INDEX KEY: 0000882095
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943047598
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 6505743000
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MARTIN JOHN C
CENTRAL INDEX KEY: 0001190578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19731
FILM NUMBER: 17573204
MAIL ADDRESS:
STREET 1: 333 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: X1
ZIP: 94404
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2017-02-01
0000882095
GILEAD SCIENCES INC
GILD
0001190578
MARTIN JOHN C
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE
FOSTER CITY
CA
94404
1
1
Executive Chairman
Common Stock
2017-02-01
4
M
0
73333
21.575
A
3204429
D
Common Stock
2017-02-01
4
S
0
73333
72.574
D
3131096
D
Non-qualified Stock Option (Right to Buy)
21.575
2017-02-01
4
M
0
73333
0
D
2018-01-30
Common Stock
73333
733330
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The options have a five year vesting schedule. 20% of the options will vest on January 30, 2009, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 30, 2013.
Sale prices reported for the transactions reported here range from $72.09 to $72.87. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
/s/ Marissa Song by Power of Attorney for John C. Martin
2017-02-03